AR and prostate carcinoma: For example, a team from The University of Texas reported the development of a novel, stable, non-toxic, small molecule peptidomimetic, which can disrupt the specific interaction between PELP1 and the androgen receptor and demonstrates a functional abrogation of androgen-induced proliferation of prostate cancer cells [32].